ArticleClinical rheumatology2025
Exploring gender-related clinical and immunological profiles in Sjögren's disease in a Chinese cohort.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Discovery of biomarkers for primary Sj ögren's syndrome based on multi-omics data, construction of diagnostic models, and clinical correlation analysis.Arthritis research & therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSjӧgren's disease (SjD) is a complex and heterogeneous disease with female predominance. However, gender-related differences in the clinical and immunological profiles of SjD patients have not been fully explored, especially after adjusting for confounding factors such as age and disease duration. This study aims to investigate these gender-specific differences in a Chinese cohort.
objectivesTo explore the gender-related clinical and immunological differences in patients with SjD by conducting a propensity score-matched (PSM) study, controlling for age and disease duration.
methodsWe retrospectively evaluated the medical records of patients with SjD who visited Peking University Peoples Hospital between January 2018 and December 2023. Using propensity scores, we matched females and males 1:1 based on age and disease duration. We then collected various clinical aspects from the medical records and compared them by gender.
resultsMale patients exhibited distinct clinical and immunological profiles compared to females. Clinically, males had a significantly higher prevalence of smoking (P < 0.001), along with lower frequencies of leukopenia (P < 0.001) and peripheral nervous system involvement (P = 0.039). Immunologically, males showed higher white blood cell counts (P = 0.002), lymphocyte counts (P = 0.033), and neutrophils levels (P=0.037), whereas females had elevated antinuclear antibody levels (P = 0.040) and erythrocyte sedimentation rates (P = 0.008). Furthermore, male patients displayed distinct lymphocyte profiles, characterized by reduced proportions of CD8+ T cells (P = 0.016), but increased natural killer cell counts.
conclusionThis study highlights significant gender-related differences in the clinical and immunological features of primary Sjögren's syndrome in a Chinese cohort. Despite sharing similar sicca symptoms with females, male patients exhibited distinct immunological and hematological profiles. These findings underscore the importance of considering gender when assessing and managing SjD patients in clinical practice. Key Points • Gender differences in SjD were assessed after adjusting for age and disease duration. • Males had less leukopenia and nervous system involvement but similar sicca symptoms. • Males showed higher NK cell counts and lower CD8+ T proportions. • Shared core symptoms but distinct immune profiles support gender-aware management.
Indexed as
Identifiers
40833704What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.